Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

Dana-Farber Researchers Unveil Promising Phase 2 Results for Targeted

A Breakthrough in Targeted Therapy: Zenocutuzumab Offers Hope for Patients with Rare NRG1-Positive Cholangiocarcinoma Cholangiocarcinoma, a rare but aggressive malignancy originating in the bile ducts, has long posed a therapeutic challenge due to its typically poor response to conventional chemotherapy and limited treatment options. This cancer can manifest in intrahepatic or extrahepatic bile ducts and is often diagnosed at advanced stages, le…

Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy—including a near doubling of progression-free survival compared with expectations with standard of care—in previously treated patients with advanced NRG1-positive cholangiocarcinoma.